{
    "clinical_study": {
        "@rank": "63645", 
        "arm_group": [
            {
                "arm_group_label": "DHEA Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral administration of a capsule containing 130 mg of dehydroepiandrosterone (DHEA) for 5 days."
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral administration of an identical capsule containing placebo for 5 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The hypothesis of this study is that DHEA administration to increase male hormone in healthy\n      normal-weight young women to levels present in women with Polycystic Ovary Syndrome will\n      cause an inflammatory response in white blood cells in the fasting state, and in response to\n      glucose ingestion."
        }, 
        "brief_title": "Effects of Androgen Administration on Inflammation in Normal Women", 
        "completion_date": {
            "#text": "April 2010", 
            "@type": "Actual"
        }, 
        "condition": "Hyperandrogenism", 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Hyperandrogenism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Acceptable health based on interview, medical history, physical examination and lab\n             tests\n\n          -  Ability to comply with requirements of the study\n\n          -  Ability and willingness to provide signed, witnessed informed consent\n\n          -  Between the ages of 18-40 years\n\n          -  Body mass index between 18 and 25\n\n          -  Normal regular monthly periods\n\n          -  No clinical evidence of androgen excess\n\n          -  No evidence of polycystic ovaries on ultrasound\n\n        Exclusion Criteria:\n\n          -  Diabetes mellitus\n\n          -  Clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric,\n             infectious and malignant disease\n\n          -  High blood pressure\n\n          -  Current or recent (within 30 days prior to study entry) use of any drugs known or\n             suspected to affect reproductive function including oral contraceptives, metformin,\n             gonadotropin releasing hormone agonists, or anti-androgens (spironolactone,\n             flutamide, etc.)\n\n          -  Use of medications that have an adverse drug interaction with DHEA therapy including\n             antipsychotics, phenothiazines, lithium, selective serotonin reuptake inhibitors,\n             triazolam, estrogen or testosterone formulations\n\n          -  Known hypersensitivity to DHEA\n\n          -  Two first-degree relatives with breast cancer or ovarian cancer\n\n          -  Documented or suspected history of recent (within 1 year) illicit drug abuse or\n             alcoholism\n\n          -  Tobacco smoking\n\n          -  Ingestion of any investigational drugs within 4 weeks prior to study onset\n\n          -  Pregnancy or lactation (less than or equal to 6 weeks postpartum)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753037", 
            "org_study_id": "Mayo-06-004680"
        }, 
        "intervention": [
            {
                "arm_group_label": "DHEA Group", 
                "description": "DHEA 130 mg administered orally for 5 days.", 
                "intervention_name": "Dehydroepiandrosterone (DHEA)", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "description": "Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Androgens", 
                "Dehydroepiandrosterone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hyperandrogenism", 
            "Inflammation", 
            "Insulin sensitivity", 
            "Body composition"
        ], 
        "lastchanged_date": "November 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Oral Androgen Administration on Hyperglycemia-Induced Inflammation in Lean Reproductive-Age Women", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Frank Gonz\u00e1lez, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "White blood cell NFkappaB activation will be assessed in response to glucose ingestion before and after 5 days of DHEA or placebo administration.", 
            "measure": "Nuclear factor kappa B (NFkappaB) activation", 
            "safety_issue": "No", 
            "time_frame": "0 and 2 hours after glucose ingestion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753037"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Frank Gonzalez", 
            "investigator_title": "Study Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Insulin sensitivity derived from an oral glucose tolerance test (OGTT) will be assessed before and after 5 days of DHEA or placebo administration.", 
            "measure": "Insulin sensitivity", 
            "safety_issue": "No", 
            "time_frame": "0 and 5 days after DHEA or placebo"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2006", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}